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Raddeanin A is one of the triterpenoid saponins in herbal medicine Anemone raddeana Regel which was
reported to suppress the growth of liver and lung cancer cells. However, little was known about its effect
on gastric cancer (GC) cells. This study aimed to investigate its inhibitory effect on three kinds of different
differentiation stage GC cells (BGC-823, SGC-7901 and MKN-28) in vitro and the possible mechanisms.
Proliferation assay and ﬂow cytometry demonstrated Raddeanin A’s dose-dependent inhibitory effect
and determined its induction of cells apoptosis, respectively. Transwell assay, wounding heal assay
and cell matrix adhesion assay showed that Raddeanin A signiﬁcantly inhibited the abilities of the inva-
sion, migration and adhesion of the BGC-823 cells. Moreover, quantitative real time PCR andWestern blot
analysis found that Raddeanin A increased Bax expression while reduced Bcl-2, Bcl-xL and Survivin
expressions and signiﬁcantly activated caspase-3, caspase-8, caspase-9 and poly-ADP ribose polymerase
(PARP). Besides, Raddeanin A could also up-regulate the expression of reversion inducing cysteine rich
protein with Kazal motifs (RECK), E-cadherin (E-cad) and down-regulate the expression of matrix
metalloproteinases-2 (MMP-2), MMP-9, MMP-14 and Rhoc. In conclusion, Raddeanin A inhibits prolifer-
ation of human GC cells, induces their apoptosis and inhibits the abilities of invasion, migration and
adhesion, exhibiting potential to become antitumor drug.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
Gastric cancer (GC) is one of the leading causes of cancer-re-
lated death around the world [1]. It is the second most common
cancer and the third leading cause of death among cancer patients
in China [2]. Currently, surgery, with better clinical therapeutic ef-
fect when combined with chemotherapy, is the dominated therapy
for GC. Increasing new antitumor agents are under investigation in
both academic and industrial research laboratories all over the
world. Nowadays, researchers have found that natural products
are important sources of chemical anticancer medicine and many
chemotherapeutic agents, directly or indirectly, derived from nat-
ural products such as paclitaxel and vincristine. It has been a hot-spot in cancer treatment research to ﬁnd antitumor drugs from
natural products.
Anemone Raddeana Regel belonging Ranunculaceae family is
used to treat cancer, rheumatism, paralysis, and pain around waist
and legs [3]. During the past 20 years, various components were
isolated and identiﬁed from this plant, among which the primary
ones are triterpenoid saponins [4]. Recent studies have suggested
that one of the triterpenoid saponins, Raddeanin A, exhibited cyto-
toxicity in vitro [5–7]. It had signiﬁcant inhibitory effect on the
growth of the tumor cells such as liver cancer and lung cancer cells
[8,9]. However, its inhibitory effect on GC cells and the related
mechanism has not yet been reported. Therefore, the purpose of
our study was to investigate its inhibitory effect on GC cells and
the related molecular mechanism.
2. Materials and methods
2.1. Cell lines and cell culture
Human GC cell lines BGC-823 (low differentiated), SGC-7901
(moderately differentiated) and MKN-28 (high differentiated) were
obtained from Type Culture Collection, Chinese Academy of
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taining 10% bovine serum, penicillin (100 U/ml) and streptomycin
(100 lg/ml) at 37 C in 5% CO2 atmosphere.2.2. Chemicals and antibodies
Raddeanin A was purchased from China National Institute for
the Control of Pharmaceutical and Biological Products
(purityP 99%) and dissolved in DMSO. RPMI-1640 medium,
bovine serum and penicillin–streptomycin were purchased from
Gibco BRL (Gaithersburg, MD, USA). Pancreatin and 3-(4, 5-dimeth-
ylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) from Bio-
sharp (Hefei, China); Annexin-V/propidium iodide (PI) apoptosis
detection kit from KeyGen Biotech Co., Ltd. (Nanjing, China);
primescript reverse transcription reagent Kit with gDNA Eraser
from TaKaRa (Dalian, China); TRIzol reagent and Power SYBR Green
PCR Master Mix from Life Technologies (Grand Island, NY); mono-
clonal mouse b-actin antibody from Sigma Chemical Co. (St. Louis,
MO). Antibody against Bcl-2 was purchased from Santa Cruz Bio-
technology (Santa Cruz, CA), and antibodies against caspase-3, cas-
pase-8, caspase-9, poly-ADP ribose polymerase (PARP), Bax,
metalloproteinases-9 (MMP-9), MMP-14, reversion inducing cys-
teine rich protein with Kazal motifs (RECK), Rhoc and E-cadherin
(E-cad) from Cell Signaling Technology (Beverly, MA).2.3. MTT assay detects the inhibition of Raddeanin A on human GC cell
lines growth (BGC-823, SGC-7901 and MKN-28)
Cells in the logarithmic growth phase were plated in 96-well
culture plates at 8  103 cells/well. After the cells treated with
Raddeanin A (2, 4, 8 or 16 lM) for 12 h, 20 ll of MTT (5 mg/ml)
solution was added to each well, followed by further 4 h MTT incu-
bation. Cells were lysed in 150 ll DMSO, and the optical densities
(ODs) were measured by ELx800 microplate reader (BioTek,
Winooski, VT) at 490 nm. The cell growth inhibition rate was calcu-
lated using the following formula: 1  ODexperiment/ODcontrol.Table 1
Sequences of primers used in the real-time PCR ampliﬁcations.
Gene primer Sequences (50-30) Length of PCR
product (bp)
Bax F: TTTGCTTCAGGGTTTCATCC 2132.4. Flow cytometric analysis of apoptosis with Annexin-V/PI double
staining
After treated with or without Raddeanin A (8, 16 lM), together
with 50 lg/ml 5-ﬂuorouracil (5-FU) for 12 h as a positive control,
about 3  105 cells were harvested and washed twice with cold
phosphate buffer saline (PBS), resuspended in 500 ll 1  binding
buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2).
About 5 ll Annexin-V and 5 ll PI were then added to the solution,
and the cells were gently vortexed and incubated for 15 min at
room temperature in the dark for ﬂow cytometric analysis.R: GCCACTCGGAAAAAGACCTC
Bcl-2 F: TCGCCCTGTGGATGACTGAG 143
R: CAGAGTCTTCAGAGACAGCCAGGA
Bcl-xL F: ATGAACTCTTCCGGGATGG 166
R: TGGATCCAAGGCTCTAGGTG
Survivin F: TTCTCAAGGACCACCGCATC 127
R: GCCAAGTCTGGCTCGTTCTC
MMP-2 F: CTCCCGGAAAAGATTGATG 96
R: GGTGCTGGCTGAGTAGAT
MMP-9 F: TCTATGGTCCTCGCCCTGAA 219
R: CATCGTCCACCGGACTCAAA
MMP-14 F: ATCTGCCTCTGCCTCACCTA 126
R: AAGCCCCATCCAAGGCTAAC
RECK F: ATCTGTTCACCCTGGAGT 96
R: TGTTGAAGTGTTTGCTTT
b-Actin F: GGCCAACCGCGAGAAGAT 134
R: CGTCACCGGAGTCCATCA2.5. Transwell assay
BGC-823 cells were starved in serum-free medium for 24 h,
resuspended in 200 ll serum-free medium with or without
Raddeanin A (4, 8 or 16 lM) and then added to the upper
chamber coated with Matrigel (5  105 cells per well), while the
lower chamber was ﬁlled with 500 ll RPMI-1640 medium
supplemented with 10% bovine serum were added. After 24 h
incubation, cells attached to the upper side of the ﬁlter mem-
brane washed twice with cold PBS while cells attached to the
bottom were ﬁxed with 75% alcohol and stained with crystal
violet. The numbers of cells in ﬁve random ﬁelds of each group
were counted by using inverted microscope.2.6. Wound healing assay
BGC-823 cells which were cultured as conﬂuent monolayers in
a 24-well plate (1  106/well) were wounded by removing a 1 mm
strip across the well with a standard 200 ll pipette tip when they
adhered to the plate surface. The wounded monolayers were then
washed twice with PBS to remove non-adherent cells before 1 ml
RPMI-1640 medium with or without Raddeanin A (4, 8 or 16 lM)
were added to the 24-well plate. After 24 h incubation, different
concentration groups were photographed by inverted micrographs.
2.7. Cell matrix adhesion assay
After BGC-823 cells were treated with or without Raddeanin A
(4, 8 or 16 lM) for 24 h, they were harvested and resuspended in
RPMI-1640 medium. About 2  105 live cells were seeded into sin-
gle well of a 96-well plate coated with ﬁbronectin. Each concentra-
tion group contained 12 wells and every 3 wells were washed
twice after 20, 40, 60 and 80 min to remove the non-adherent cells.
At last, discarded the medium, 20 ll of MTT solution and 100 ll
RPMI-1640 mediumwere added to each well for a further 4 h incu-
bating. Similar to MTT assay, ODs were measured and the cell
adhesion inhibition rates were calculated based on the means of
three wells.
2.8. RNA puriﬁcation and real time PCR (RT-PCR)
Total RNA was isolated by TRIzol reagent and reverse-tran-
scribed into cDNA using the TaKaRa RT reagent kit and was quan-
tiﬁed by ABI 7500 fast RT-PCR System. The primers for available
gene were designed using Primer Express shown in Table 1. Cycle
threshold (Ct) values were obtained graphically for the target
genes and b-actin. DCt = Cttarget genes  Ctendogenous reference gene.
DDCt = DCttreated samples  DCtcontrol samples. The relative fold change
in gene expression was calculated as 2DDCt.
2.9. Western blot analysis
Proteins were extracted with RIPA buffer containing protease
inhibitor cocktail and the concentration was determined using
Bradford assay. Equal amounts of protein (20 lg) from each sample
was separated by 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred onto a polyvinylidene ﬂuoride
Fig. 1. (A) Anti-proliferation of Raddeanin A on human GC cells. MTT assay showed that after three human GC cells were treated by different concentrations (2–16 lM) of
Raddeanin A or 0.1% DMSO for 12 h, the inhibition rates of three cells showed dose-dependent manner. ⁄P < 0.05. (B) Flow cytometric analysis of human GC cells apoptosis
induced by Raddeanin A using Annexin-V/PI staining. The left lower region of each quadrant shows the viable cells (Annexin-V/PI). The right lower region represents the
early stage apoptotic (Annexin-V+/PI). The top right region contains the nonviable necrotic cells (Annexin-V+/PI+).
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bated for 1 h at room temperature with 5% skim milk. All primary
antibodies were diluted in phosphate buffer saline with Tween
(PBST, 135 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM K2HPO4
and 0.05% Tween-20) containing 5% skim milk. Afterwards, the
membranes were incubated with appropriate primary antibodies
overnight at 4 C. After washing three times with PBST and incu-
bated with HRP-linked secondary antibodies (anti-rabbit or anti-
mouse IgG) for1 h at room temperature, the signal was visualized
using an ECL detection kit (Millipore, Billerica, MA). The b-actin
was taken as a loading control. Western blot analysis was repeated
independently for 3 times.2.10. Statistical analysis
SPSS13.0 software was utilized to analyze the datas which were
expressed as the mean ± SD. One-way ANOVA test was used to
examine the statistical difference of experimental data between
the groups. The signiﬁcance was deﬁned as P < 0.05.3. Results
3.1. The inhibition of Raddeanin A on human GC cells proliferation
in vitro
MTT assay results showed that the inhibition rates of three hu-
man GC cells presented dose-dependent manner after treated by
different concentrations of Raddeanin A for 12 h. When the con-
centration of Raddeanin A reached to 16 lM, the inhibition rates
for BGC-823, SGC-7901 and MKN-28 cells rose to 92.84% ± 4.5%,
87.74% ± 4.3% and 94.31% ± 4.9% (Fig. 1A) and the IC50 value of
these cells were 5.34, 6.61 and 4.98 lM, respectively.
3.2. Raddeanin A induced GC cells apoptosis
To further conﬁrm Raddeanin A’s induction of cell apoptosis,
Annexin-V/PI double staining was applied for the ﬂow cytometric
analysis after the cells were treated for 12 h. From 8 to 16 lM,
early apoptosis rates of BGC-823, SGC-7901 and MKN-28 cell in-
creased from 19.08% to 82.16%, from 18.31% to 34.01% and from
Fig. 2. (A) Transwell assay detected the effects of Raddeanin A’s invasion on GC cells. After the treatment cells migrated across 8 lm diameter pores to the lower chamber for
24 h, light microscopic images of different concentrations (400) were taken. The white dot was the 8 lm diameter pores of transwell chamber. (B) Wound assay detected
migration of Raddeanin A for human GC cells, which were photographed 24 h after wounding (100). White lines indicate wound edges. Cells between the two white lines
were the ones which migrated to the wound area. (C) Cell matrix adhesion assay was used to detect Raddeanin A’s adhesion for GC cells. (D) Each point in curve was the
inhibition rate of cell adhesion of different concentrations (4, 8 or 16 lM) at different periods (20, 40, 60 and 80 min).
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treated with 50 lg/ml 5-Fu for 12 h. The early apoptosis rate of
the each cell line was 21.32% (BGC-823), 15.44% (SGC-7901) and
32.09% (MKN-28), respectively (Fig. 1B). In summary, the above
results suggested that Raddeanin A could effectively induce apop-
tosis, and the apoptosis rates of three cells all presented a dose-
dependent manner.
3.3. Raddeanin A inhibited the invasion and migration abilities of the
GC cells
In order to measure the effect of invasion and migration abili-
ties of Raddeanin A on human GC cell, low differentiated BGC-
823 cells were chosen as the target cells. As shown in Fig. 2A, the
result of transwell assay showed that after BGC-823 cells were
treated with or without Raddeanin A (4, 8 or 16 lM) for 24 h, the
number of the cells invaded across 8 lm diameter pores to the
lower chamber markedly decreased compared with control group,
indicating that Raddeanin A could suppress the invasion of GC.
Meanwhile, the treated cells in the 24-well plate migrated to the
whole wound area markedly decreased compared with control
group (Fig. 2B) which suggested that Raddeanin A could also sup-
press the migration of GC cells. In addition, the inhibition rates of
both invasion and migration of Raddeanin A on GC cells presented
a dose-dependent manner.
3.4. Raddeanin A inhibited GC cells’ adhesion
In order to evaluate the effect of Raddeanin A on GC cells’ adhe-
sion, the cell matrix adhesion assay was performed. Similar to theresults of transwell invasion assay and wound assay, the adhesion
rates of cells treated with Raddeanin A at all time points were
lower than those of control group (Fig. 2C). Further data
demonstrated that the inhibitory rate of adhesion increased as
concentrations and time rose up (Fig. 2D). Consequently,
Raddeanin A could dramatically inhibit the adhesion of GC cells
to ﬁbronectin and the inhibition rates presented a dose- and
time-dependent manner.3.5. Changes of the apoptosis-related mRNA and proteins
In order to investigate the potential mechanism involved in
Raddeanin A inducing apoptosis, RT-PCR and Western blot were
applied to analyze the mRNA and protein changes of the apopto-
sis-related molecules. BGC-823 (Fig. 3A), SGC-7901 (Fig. 3B) and
MKN-28 (Fig. 3C) cells were treated for 12 h and all the three re-
sults showed that the Bax level signiﬁcantly increased while Bcl-
2, Bcl-xL and Survivin levels decreased in a dose-dependent man-
ner. The ratios of Bax/Bcl-2 was further calculated, which increased
in a dose-dependent manner (Fig. 3D). In addition, expressions of
caspase family proteins and PARP protein were detected by Wes-
tern blot, as shown in Fig. 3E, whose results demonstrated gradual
increase of cleaved caspase-8 protein in a dose-dependent manner;
while procaspase-3, procaspase-9 and pro-PARP decreased, indi-
cating that Raddeanin A could signiﬁcantly activated caspase-3,
caspase-8, caspase-9 and PARP. To summarize, Raddeanin A in-
duced the apoptosis of GC cells by up regulating Bax expression
and down regulating the Bcl-2, Bcl-xL and Survivin expressions
as well as activating the caspase-cascade response.
Fig. 3. Real time PCR and Western blot analysis of the apoptosis-associated molecules. After BGC-823 (A), SGC-7901 (B) and MKN-28 (C) cells were treated for 12 h with or
without Raddeanin A (8, 16 lM), the mRNA levels of apoptosis-related genes (Bax, Bcl-2, Bcl-xL, and Survivin) were determined by RT-PCR. The b-actin was taken as a loading
control and 5-FU (50 lg/ml) as a positive control. (D) The Bax/Bcl-2 ratios of mRNA levels in GC cells treated with 8 or 16 lM Raddeanin A. ⁄P < 0.05. The data represented
from three independent experiments. (E) Representative images of Western blot.
Fig. 4. (A) RT-PCR analysis of the invasion-related molecules. After BGC-823 cells were treated with or without Raddeanin A (4, 8 or 16 lM) for 24 h, the mRNA levels of
invasion-related genes (MMP-2, MMP-9, MMP-14, RECK) were detected. The b-actin was as an internal control. ⁄P < 0.05. The data represent the means ± SD from three
independent experiments. (B) Representative images of Western blot. After BGC-823 cells were treated with or without Raddeanin A (4, 8 or 16 lM) for 24 h, the expression
changes of the proteins closely associated with invasion and adhesion (RECK, MMP-9, MMP-14, Rhoc, E-cad) were detected. The b-actin was as an internal control. The images
were representative of three independent experiments.
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In order to investigate the potential mechanism of Raddeanin
A’s inhibition of cell invasion, RT-PCR and Western blot were uti-
lized to detect the invasion-related molecules such as RECK, MMPs.
The results of both RT-PCR (Fig. 4A) and Western blot (Fig. 4B)
showed that RECK expression signiﬁcantly increased while MMP-
2, MMP-9, MMP-14 expressions were declined as dose decreased.
Besides, changes of Rhoc expression were investigated. Similar to
the MMPs family, it revealed a decreasing trend with the increaseof drug concentrations. Raddeanin A was found in the experiment
to markedly prevent GC cells from adhering to ﬁbronectin. There-
fore, the E-cad expression which was closely associated with adhe-
sion was further detected, ﬁnding that the treated BGC-823 cells
resulted in a dose-dependent increase of E-cad.
4. Discussion
Apoptosis, or programmed cell death, is a well-documented
phenomenon in many cellular systems, which plays a crucial role
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death. Caspase-cascade is a central part of cell apoptosis and regu-
lated by various kinds of molecules, such as Bcl-2 family proteins.
Generally, the caspase family proteases can be activated through
two pathways: one is the death signal-induced, death receptor-
mediated pathway; the other is the mitochondrion-dependent
pathway. Once the speciﬁcity substrate such as PARP has been cut
by the cleavage of caspases, apoptosis will be induced [10,11].
Therefore, the research of caspase is signiﬁcant for exploring new
targets of cancer treatment. The present research used ﬂow cytom-
etry to detect cell apoptosis rate, ﬁnding the apoptosis rates of three
GC cells increased signiﬁcantly when treated with Raddeanin A (8,
16 lM) for 12 h. Further Western blot data revealed that the cas-
pase-3, 8, 9 and PARP were activated by Raddeanin A (8, 16 lM),
which indicated the cell apoptosis. Therefore, we inferred that acti-
vating caspase cascade is the mechanism of Raddeanin A inducing
cell apoptosis. However, more research is in need to investigate
Raddeanin A inducing the apoptosis of GC cells through endoge-
nous pathways or exogenous pathways or through both.
Although the caspases is a central point to apoptosis, their acti-
vation is regulated by many other factors, among which Bcl-2 fam-
ily plays a pivotal role in either inhibiting (Bcl-2, Bcl-xL) or
promoting (Bax, Bak) cell death [12,13]. Recently, it has been re-
ported that Bax inactivating Bcl-2 proteins regulates the apoptosis
mediated by mitochondria and the ratio of Bax to Bcl-2 proteins in-
creases during apoptosis induction [14].Therefore, we continued to
detect the expression change of Bcl-2 family. As shown in Fig. 3E,
the protein level of Bax increased in a dose-dependent manner,
while the Bcl-2 protein decreased. Further data revealed that the
ratio of Bax/Bcl-2 proteins also increased in a dose-dependent
manner (Fig. 3D). These results partly interpreted the molecular
mechanism of Raddeanin A inducing human GC cells in vitro.
Invasion and metastasis, the main reasons for shortening long-
term survival, are regarded as essential features of cancer. There-
fore, in addition to apoptosis-inducing, inhibiting metastasis is also
the key to cancer treatment. The degradation of the extracellular
matrix plays a crucial role in tumor invasion andmetastasis. MMPs,
a family of zinc-dependent endopeptidases, could degrade the
extracellular matrix, thus promoting the invasion and metastasis
of cancer cells. MMP-2, MMP-9, MMP-14 are the important mem-
bers of this family [15,16], which were reported to excessively ex-
press in breast cancer and colorectal cancer, closely associated
with tumor invasion and metastasis [17–23]. The present study ob-
served the changes of invasion and migration by transwell and
wounding heal assays, ﬁnding that the inhibition rates of GC cells
of invasion and migration exhibited dose-dependent after treated
with Raddeanin A for 24 h. RT-PCR and Western blot analysis
showed that the expression of MMP-2, MMP-9 and MMP-14 de-
creased in a dose-dependent manner. The expression of RECK was
further detected, as it is a critical tumor suppressor that can
potently inhibit angiogenesis and metastasis of tumor and closely
related to the MMPs family [24,25]. The mechanism may be due
to negative regulation of at least MMP-9, MMP-2 and MMP-14’s
activation to suppress the invasive and metastatic potentials
[26–28]. The results showed that RECK expression signiﬁcantly
increased, contrary to that of the MMPs family. So, RECK gene
negatively regulating the expression of MMPs family was supposed
to be a key mechanism of Raddeanin A inhibiting invasion and
metastasis of GC cells. However, tumor invasion and metastasis
were multi-step processes with complex molecular mechanism,
which requires further experiments to explore other possible
molecular mechanisms.
According to the above results, it comes to the conclusion that
Raddeanin A could inhibit proliferation of human GC cells and
induce its apoptosis. Its induction of apoptosis may activate the
caspase-cascades and up-regulate the expression of Bax, down-regulate the expression of Bcl-2, Bcl-xL and Survivin. Raddeanin
A could inhibit invasion, migration and adhesion of BGC-823 cells.
Its molecular mechanism may lie on up-regulating the expression
of RECK, E-cad and down-regulating the expression of MMP-2,
MMP-9, MMP-14 and Rhoc. These ﬁndings provide an experiment
basis for Raddeanin A as chemotherapy drugs against GC cells,
thereby facilitating the development of new anticancer agents.
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